Ocugen Provides Business Update with Second Quarter 2025 Financial Results
1. Initiated dosing in OCU410ST Phase 2/3 clinical trial for Stargardt disease. 2. OCU400 Phase 3 trial on track for 2026 BLA filing. 3. Signed term sheet for exclusive rights to OCU400 in Korea worth $11 million. 4. Positive interim results bolster OCU410 potential for vision restoration. 5. Cash runway extends to Q1 2026, aiming for significant clinical developments.